Search

ImmunityBio Inc

Geschlossen

BrancheGesundheitswesen

7.79 -0.64

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.59

Max

7.79

Schlüsselkennzahlen

By Trading Economics

Einkommen

-230M

-863M

Verkäufe

7M

51M

EPS

-0.08

Gewinnspanne

-1,684.596

Angestellte

684

EBITDA

378M

-222M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+66.88% upside

Dividenden

By Acuity

Nächstes Ergebnis

2. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

905M

8.4B

Vorheriger Eröffnungskurs

8.43

Vorheriger Schlusskurs

7.79

Nachrichtenstimmung

By Acuity

50%

50%

150 / 340 Ranking in Healthcare

ImmunityBio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Aug. 2026, 19:16 UTC

Immunitybio Inc. shares are lower today amid rising crude oil prices and geopolitical tensions, despite remaining above their 20-day moving average.

20. Aug. 2026, 23:06 UTC

Immunitybio Inc. shares are lower in after-market trading, declining since Thursday's close. The asset remains above its 20-day moving average.

19. Aug. 2026, 19:26 UTC

Social Media

Immunitybio Inc shares are higher Wednesday, buoyed by social media discussions anticipating prices between $8 and $12. The stock remains above its 20-day moving average.

18. Aug. 2026, 23:06 UTC

Immunitybio Inc shares are lower in after-market hours, with no specific news identified. Broader market conditions reflect a decline in U.S. stocks.

14. Aug. 2026, 19:36 UTC

Immunitybio shares are lower amid broader market sentiment following a reported decline in retail sales, raising concerns about consumer demand and economic health.

10. Aug. 2026, 19:16 UTC

News

ImmunityBio Inc. appoints Dr. Jim Yong Kim as Vice Chairman. Shares are lower today amid broader market pressure from a U.S. jobs report.

7. Aug. 2026, 23:06 UTC

Immunitybio Inc's shares are lower in after-market hours, with no specific news driving the decline. The stock remains above its 20-day moving average.

6. Aug. 2026, 23:11 UTC

Immunitybio Inc's shares are higher in after-market trading, reflecting a slight increase since Thursday's close, though still below the 20-day moving average.

5. Aug. 2026, 19:26 UTC

Immunitybio Inc's shares are higher today amid positive market sentiment. The stock is recovering from earlier weakness despite remaining below its 20-day moving average.

4. Aug. 2026, 23:46 UTC

Immunitybio Inc. shares are trading roughly flat in after-market hours. The asset remains significantly below its 20-day moving average.

3. Aug. 2026, 23:21 UTC

Immunitybio Inc shares rose in after-market trading, settling higher since Monday's close. The stock remains below its 20-day moving average.

1. Aug. 2026, 00:02 UTC

Immunitybio Inc shares are higher in after-market trading, reflecting a notable increase since Friday's close amid broader market dynamics.

31. Juli 2026, 23:06 UTC

Immunitybio Inc's shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

30. Juli 2026, 19:29 UTC

Immunitybio Inc is trading higher, recovering from an earlier drop. The stock has rebounded significantly since Wednesday's close, despite six consecutive lower daily closes.

29. Juli 2026, 23:41 UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

28. Juli 2026, 20:06 UTC

News

ImmunityBio Inc is under investigation for potential wrongdoing, contributing to its decline today. Shares remain lower since Monday's close, marking six consecutive sessions of losses.

27. Juli 2026, 19:16 UTC

Immunitybio Inc. shares are lower, continuing a four-session decline amid broader market pressures and a significant drop in oil prices.

24. Juli 2026, 23:06 UTC

Immunitybio Inc shares are higher in after-market hours following Friday's close, settling with a cumulative increase after earlier gains. No specific news was identified.

23. Juli 2026, 09:16 UTC

Immunitybio Inc shares are higher in pre-market hours, continuing an upward trend since Wednesday. This movement occurs amid broader market pressures from disappointing tech earnings.

22. Juli 2026, 19:11 UTC

Immunitybio Inc's shares are lower today, diverging from recent gains. The stock is seeing unusually high trading volume amid rising crude oil prices.

21. Juli 2026, 18:06 UTC

Immunitybio Inc is trading higher during Tuesday's session amid positive market sentiment. No specific company news was identified to explain the movement.

20. Juli 2026, 23:46 UTC

Immunitybio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Peer-Vergleich

Kursveränderung

ImmunityBio Inc Prognose

Kursziel

By TipRanks

66.88% Vorteil

12-Monats-Prognose

Durchschnitt 13 USD  66.88%

Hoch 15 USD

Tief 12 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ImmunityBio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Stimmung

By Acuity

150 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
help-icon Live chat